Overview
Artificial Intelligence (AI) and machine learning solutions are poised to reshape healthcare delivery as the landscape of medical AI have matured considerably. Just a few years ago, only a handful of medical AI algorithms were used successfully to detect diseases from medical images. Fast forward to today, there is an increase in the number of robust use cases of AI in healthcare. However, chal...
Artificial Intelligence (AI) and machine learning solutions are poised to reshape healthcare delivery as the landscape of medical AI have matured considerably. Just a few years ago, only a handful of medical AI algorithms were used successfully to detect diseases from medical images. Fast forward to today, there is an increase in the number of robust use cases of AI in healthcare. However, challenges remain. The commercialisation of medical AI systems for deployment into existing healthcare systems inherently lies many complex issues and requires careful navigation to ensure its adoption.
At this upcoming journal club, experts on AI in Healthcare will be discussing various topics on the commercialisation of AI research, including:
- Is the healthcare system ready for AI?
- Are patients ready for AI?
- How do we navigate the regulatory pathways?
- How do we cross the 'Valley of Death' en route to commercialisation?
- How can we generate revenue from AI?
Date: 28 April 2022, Thursday
Time: 7:00pm - 8:00pm
Venue: SGInnovate
Programme:
7:00pm - 7:05pm: Welcome Remarks
7:05pm - 8:00pm: Panel Discussion and Q&A on Commercialising AI Research in Health: Crossing the Valley of Death with:
- Christian Teo Head of Novartis Biome Innovation Hub (APAC-MEA), Novartis
- Chik Wai Chiew, CEO & Executive Director, Heritas Capital
- Dorothea Koh, Founder & CEO, BotMD
- A/Prof Henry Ho, Chairman, Division of Surgery and Surgical Oncology, SGH and NCCS and Director, The Innovation Centre, SingHealth Duke-NUS
- A/Prof Tan Cher Heng, Assistant Chairman Medical Board (Clinical Research and Innovation) and Senior Consultant - Department of Diagnostic Radiology, Tan Tock Seng Hospital
- Moderator: A/Prof Daniel Ting, Director, SingHealth AI Programme
Christian Teo, Head of Novartis Biome Innovation Hub (APAC-MEA), Novartis
As Head of Novartis' Biome Digital Innovation Lab, Christian Teo focuses on ensuring the success of Novartis' digital health partnerships and activities across the Asia Pacific, Middle East and Africa region, supporting innovation teams in delivering improved patient outcomes at scale. Christian has advised business leaders in open innovation strategy, design thinking implementation, and new product development as a corporate innovation professional. Before joining Novartis, Christian was part of the Business Model Factory for Deloitte Tohmatsu Venture Support in Japan, providing open innovation consulting for large corporations and government agencies. He was also an innovation lead for Deloitte SEA and OCBC Bank's Fintech & Innovation Group.
Chik Wai Chiew, CEO & Executive Director, Heritas Capital
Chik Wai Chiew is the Executive Director & CEO of Heritas Capital Management, a Singapore-based private equity and venture capital investor in healthcare, education and technology sectors across Asia Pacific. Heritas’ healthcare portfolio investments include leading health-tech ventures throughout Asia such as Holmusk, Tessa Therapeutics, Hummingbird Bioscience, Alodoktor, Strand Life Sciences, MFine.
Wai Chiew has over 20 years of experience in global investment management and strategic business development, having served various roles in Temasek Holdings, A*Star, EDB, and World Economic Forum, etc. He also actively serves as a director on multiple boards to advocate sustainable growth and sound governance.
Wai Chiew was awarded the Glaxo-EDB scholarship and holds a BA in Economics from Cambridge University, UK; MA from Yale University, USA; and completed EMBA (conducted in Mandarin) from Cheung Kong Graduate School of Business, China.
Dorothea Koh, Founder & CEO, BotMD
Dorothea Koh is the CEO & Co-Founder of Bot MD, a Y-Combinator backed startup with the mission of empowering doctors. Since 2018, the Bot MD A.I. Assistant has been used by 18,000+ doctors to instantly search for hospital information, and has helped monitor over 4,000 COVID-19 patients through powering popular chat platforms such as WhatsApp, Viber and Telegram. Prior to starting Bot MD, Dorothea was the General Manager of Baxter for Indonesia, Singapore & Philippines where she was responsible for country wide operations in these markets. She has 15 years of healthcare industry experience across several geographies including China where she helped to innovate and launch new business models.
Dorothea graduated summa cum laude from Northwestern with a B.S. in Biomedical Engineering and Economics, and received her M.S. in Bioengineering from Stanford. She is also an alumni of the Stanford Byers Biodesign Innovation Program and currently has 10 patents published and pending.
A/Prof Henry Ho, Chairman, Division of Surgery and Surgical Oncology, SGH and NCCS and Director, The Innovation Centre, SingHealth-DukeNUS
Clinical Associate Professor Henry HO has been appointed as the Chairman for Division of Surgery and Surgical Oncology, Singapore General Hospital and National Cancer Centre Singapore; Academic Chair for Surgery Academic Clinical Program, SingHealth with effect from 1 April 2022. Currently A/Prof Henry is also holding the appointment as Director for SingHealth Duke-NUS Innovation Centre.
A/Prof Henry is a urological surgeon that specializes in robotic surgery for urological cancers such as prostate & kidney. He received his MBBS and Master of Medicine (Surgery) from the National University of Singapore. After his accreditation as a Urologist, he further specializes with fellowships in robotic surgery in University of Innsbruck, Austria and Stone surgery in Hamburg, Germany.
A/Prof Henry is an advocate for innovation in his clinical career. He is an early adopter of new technology with robust scientific methodology. Amongst his many publications, the randomized control trial on bipolar technology for prostate enlargement changes the practice of urologist internationally.
He went on to be an innovator with the invention of Mona LisaTM transperineal prostate biopsy device (Biobot Surgicals Pte Ltd). He brought this project from a research project to commercial company. The device provide safe and accurate diagnosis of prostate cancer in men. It is used in many Singapore hospitals, Germany, Australia and China.
A/Prof Henry also contributes to the Singapore innovation ecosystem. He was the first doctor in SGH/SingHealth to be awarded the Singapore-Stanford Biodesign Fellowship Award by A*STAR in 2011. He started the Medical technology Office (MTO) in Singhealth to help more clinicians onto this innovation journey. Its goal is to nurture doctors, nurses and allied health with grants and technology matching to become clinician-innovators. His NMRC is Co-chair of the Clinician-innovator taskforce and Chair for clinician-innovator development grant.
A/Prof Henry leads the clinical test-bedding and adoption in Singhealth-DUKE NUS Academic Medicine Innovation Institute which aims to facilitate implementation of technologies with external partners into the healthcare system. to imbue such vibrant exchange and collaboration (Digital, technologyand process), there will be a healthcare Innovation and transformation center.
A/Prof Tan Cher Heng, Assistant Chairman Medical Board (Clinical Research and Innovation) and Senior Consultant - Department of Diagnostic Radiology, Tan Tock Seng Hospital
Dr Tan Cher Heng graduated with a medical degree from NUS and EMBA from Insead. A certified radiologist, he also serves as Assistant Chairman Medical Board (Clinical Research and Innovation) at TTSH, Assistant Dean (Clinical Research) at LKC School of Medicine, and Executive Director at Centre for Healthcare Innovation. His collaboration with A*STAR, RadiLogic, received the National Health Innovation and Productivity Award in 2021.
Moderator's Profiles:
A/Prof Daniel Ting - Director, SingHealth AI Programme
Associate Professor Daniel Ting is the Director of SingHealth AI Programme, Head of AI and Digital Innovation in Singapore Eye Research Institute (SERI), Associate Professor in Ophthalmology with Duke-NUS Medical School Singapore, and Consultant Vitreo-Retinal Surgeon in Singapore National Eye Centre.
The SingHealth Cluster AI Program was established in April 2021 with the vision to harness the power of AI for Academic Medicine of Tomorrow. The key focus areas for this programme are to develop more AI-powered clinical solutions using different cutting edge technologies and rapidly bring these technologies to the bedside for clinical implementation and scale them in the global setting. Furthermore, this programme hopes to build a critical mass of the current and next generation of AI literate practitioners within the healthcare space.
In the global setting, Dr Ting serves in several AI executive committees (STARD-AI, DECIDE-AI, American Academy of Ophthalmology) and AI editorial boards (NPJ Digital Medicine, Frontiers in Medicine and Digital Health). To date, he has published >200 peer-reviewed papers in highly prestigious journals such as JAMA, NEJM, Lancet, Nature Medicine, etc., and recently been ranked the world’s most influential deep learning researcher across clinical and technical domains in healthcare for the past ten years (2010-2021) by the ExpertScape. He was also the visiting Fulbright Scholar to Johns Hopkins University in 2017.
